Acceleron and Celgene have initiated a second phase 2 clinical study of ACE-011. It is intended to treat chemotherapy-induced anemia in patients with metastatic breast cancer.
Reportedly, phase 2 clinical trial is a randomized, double-blind, placebo-controlled study designed to evaluate the potential of ACE-011. ACE-011 is a novel therapeutic agent that has shown to increase levels of red blood cells and hemoglobin and stimulate new bone formation.
John Knopf, CEO of Acceleron, said: “Our discovery of a novel class of anemia therapies comes at a critical time for cancer patients. Many of these patients suffer from an inadequate response to existing therapies or remain untreated due to safety concerns with erythropoietin-based therapies for chemotherapy-induced anemia.”
“We are excited to be working with a pre-eminent global biopharmaceutical company like Celgene, which is experienced in maximizing the clinical and commercial potential of disease-altering compounds, to advance the development of this unique molecule, which could replenish red blood cells and has been shown to inhibit the growth and metastasis of tumors in nonclinical animal models of breast cancer,” he added.